# Nuclide record hd21 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/hd21/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "hd21", "NCT02661503" ;
  schema:name "GHSG HD21"@en ;
  schema:description "A new brentuximab-based intensive regimen matched Europe's most effective (and most toxic) chemotherapy with far fewer side effects."@en ;
  schema:url <https://nuclide.cc/trials/hd21/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02661503> ;
  nuclide:status "positive" ;
  nuclide:phase "3" ;
  nuclide:technologies <https://nuclide.cc/technologies/pet-adapted-therapy/> .